<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04090164</url>
  </required_header>
  <id_info>
    <org_study_id>R.18.02.34.R1.R2</org_study_id>
    <nct_id>NCT04090164</nct_id>
  </id_info>
  <brief_title>Association of Hepatitis C Virus With Breast Cancer</brief_title>
  <official_title>Association of Hepatitis C Virus Seropositivity With Breast Cancer Prognosis and Treatment Outcome</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Mansoura University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Mansoura University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Hepatitis C viral infection is a major health problem in Egypt. The management of breast&#xD;
      cancer patients is often complicated by the presence of associated HCV infection. This study&#xD;
      aims at investigating the epidemiological association of the two conditions. It will also&#xD;
      investigate the possible correlation with treatment outcome.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Breast cancer is the most common cancer in adult Egyptian females. The world's highest&#xD;
      prevalence of hepatitis C virus is found in Egypt. Several investigators examined the&#xD;
      epidemiological association of HCV with breast cancer. Published literature reports&#xD;
      conflicting results regarding the HCV association with breast cancer incidence.&#xD;
      Population-based studies from HCV-endemic area demonstrated increased breast cancer incidence&#xD;
      in HCV-positive women younger than 50 years. On the other hand, population studies from&#xD;
      HCV-low prevalence regions failed to detect an association of the virus with breast cancer.&#xD;
&#xD;
      HCV seropositive patients constitute a large sector of oncology patients treated in Egyptian&#xD;
      practice. HCV infection with or without clinically-significant liver disease impose several&#xD;
      therapeutic, social and logistic problems. Recently, investigators from Mansoura University&#xD;
      reported their findings among breast cancerpatients. According to these data, HCV-positive&#xD;
      breast cancer patients had several markers of disease aggression such as large tumor size,&#xD;
      high tumor grade and nodal infiltration. Moreover, HCV-NS4 (non-structural protein-4) blood&#xD;
      levels positively correlated with the level of the known breast cancer marker CA15-3.&#xD;
&#xD;
      In the current study, the investigators will investigate the incidence of HCV seropositivity&#xD;
      in breast cancer patients and an age-matched control group. The study also examines the&#xD;
      association of HCV status on the patients' baseline characteristics such as tumor stage and&#xD;
      grade and with patients' treatment plan and treatment outcome.&#xD;
&#xD;
      Specifically, the aims of the study are the following:&#xD;
&#xD;
        1. To test if HCV seropositivity is associated with breast cancer diagnosis in Egyptian&#xD;
           population.&#xD;
&#xD;
        2. To test if HCV-positive patients harbour more aggressive breast tumors.&#xD;
&#xD;
        3. To test if HCV-positivity affects management decision in breast cancer patients.&#xD;
&#xD;
        4. To test if HCV-positive patients suffer more frequent adverse effects to breast cancer&#xD;
           treatment.&#xD;
&#xD;
        5. To compare disease-free survival of HCV seropositive breast cancer patients vs.&#xD;
           seronegative patients.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">September 1, 2019</start_date>
  <completion_date type="Actual">June 1, 2020</completion_date>
  <primary_completion_date type="Actual">June 1, 2020</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Control</observational_model>
    <time_perspective>Retrospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Prevalence of HCV Seropositivity in Breast Cancer Patients.</measure>
    <time_frame>This outcome will be assessed through study completion, an average of 6 months.</time_frame>
    <description>Percentage of patients with breast cancer with positive anti-HCV serological test.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Disease-related Events</measure>
    <time_frame>at the date of last patients' visit recorded on her file. Patients should be censored at least 12 months from the time of diagnosis.</time_frame>
    <description>The number of events related to breast cancer diagnosis. Disease-free survival (DFS) was calculated as the time from the date of breast cancer diagnosis to the date of last follow-up or the date of first breast cancer-related event. At the time of analysis, median survival has not been reached.</description>
  </secondary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Actual">650</enrollment>
  <condition>Breast Cancer</condition>
  <condition>Hepatitis C</condition>
  <arm_group>
    <arm_group_label>Study group</arm_group_label>
    <description>The data of breast cancer patients treated at OCMU in the last 10 years will be retrieved from the hospital data filing system. All consecutive patients with biopsy-proven invasive breast cancer will be included.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control group</arm_group_label>
    <description>A group of age-matched women from the same geographical distribution who are healthy volunteers or hospital patients without cancer diagnosis will serve as a control group for the HCV prevalence. We aim at a sample size with a study-to-control ratio of 1:3.</description>
  </arm_group>
  <eligibility>
    <study_pop>
      <textblock>
        Retrospective analysis of all consecuitive patients on Oncology Center of Mansoura&#xD;
        University (OCMU) database.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Biopsy-proven invasive breast cancer.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patients with unknown viral marker status.&#xD;
&#xD;
          -  Patients who did not complete their management at OCMU.&#xD;
&#xD;
          -  Patients with multiple cancer diagnoses.&#xD;
&#xD;
          -  Patients with virus-unrelated hepatic pathology.&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Mansoura University Oncology Center</name>
      <address>
        <city>Mansourah</city>
        <state>DK</state>
        <zip>35516</zip>
        <country>Egypt</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Egypt</country>
  </location_countries>
  <reference>
    <citation>Su FH, Chang SN, Chen PC, Sung FC, Su CT, Yeh CC. Association between chronic viral hepatitis infection and breast cancer risk: a nationwide population-based case-control study. BMC Cancer. 2011 Nov 24;11:495. doi: 10.1186/1471-2407-11-495.</citation>
    <PMID>22115285</PMID>
  </reference>
  <reference>
    <citation>Attallah AM, El-Far M, Abdelrazek MA, Omran MM, Mahmoud AZ, Khalifa HS, Ahmed MM, El-Dosoky I. HCV nonstructural protein 4 is associated with aggressiveness features of breast cancer. Breast Cancer. 2018 May;25(3):297-302. doi: 10.1007/s12282-017-0829-1. Epub 2017 Dec 28.</citation>
    <PMID>29285674</PMID>
  </reference>
  <reference>
    <citation>El-Ghitany EM, Farghaly AG. Geospatial epidemiology of hepatitis C infection in Egypt 2017 by governorate. Heliyon. 2019 Aug 17;5(8):e02249. doi: 10.1016/j.heliyon.2019.e02249. eCollection 2019 Aug.</citation>
    <PMID>31463388</PMID>
  </reference>
  <verification_date>September 2020</verification_date>
  <study_first_submitted>January 14, 2018</study_first_submitted>
  <study_first_submitted_qc>September 13, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">September 16, 2019</study_first_posted>
  <results_first_submitted>August 14, 2020</results_first_submitted>
  <results_first_submitted_qc>September 24, 2020</results_first_submitted_qc>
  <results_first_posted type="Actual">October 19, 2020</results_first_posted>
  <last_update_submitted>September 24, 2020</last_update_submitted>
  <last_update_submitted_qc>September 24, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">October 19, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Mansoura University</investigator_affiliation>
    <investigator_full_name>Osama Hussein</investigator_full_name>
    <investigator_title>Professor of surgery (surgical oncology)</investigator_title>
  </responsible_party>
  <keyword>Breast cancer</keyword>
  <keyword>Hepatitis C virus</keyword>
  <keyword>Prognosis</keyword>
  <keyword>Epidemiology</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hepatitis A</mesh_term>
    <mesh_term>Hepatitis C</mesh_term>
    <mesh_term>Breast Neoplasms</mesh_term>
    <mesh_term>Hepatitis</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol and Statistical Analysis Plan</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>May 20, 2020</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/64/NCT04090164/Prot_SAP_000.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <recruitment_details>The Hospital medical record system was searched to identify patients with the &quot;malignant neoplasm of the breast&quot; diagnosis. The information of an un-selected sample of 650 patients was retrieved from the system. Two-hundred forty-five patients with incomplete data were excluded. The remaining 405 patients were subjected for further analysis.</recruitment_details>
      <pre_assignment_details>The study group was retrospectively extracted from hospital file. However, The &quot;Dakahlia Governorate adult female Population&quot; is a historical control group derived from the raw data of a previous study. As such, this control group has not been recruited in the current study.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Study Group</title>
          <description>The data of breast cancer patients treated at OCMU in the last 10 years will be retrieved from the hospital data filing system. All consecutive patients with biopsy-proven invasive breast cancer will be included.</description>
        </group>
        <group group_id="P2">
          <title>Dakahlia Governorate Adult Female Population</title>
          <description>One-hundred forty-five adult females from Dakahlia governorate were sampled in a published population-based cross sectional study from 2015 to 2017.&#xD;
[El-Ghitany EM, Farghaly AG (2019) Geospatial epidemiology of hepatitis C infection in Egypt 2017 by governorate. Heliyon 5 (8):e02249. doi:10.1016/j.heliyon.2019.e02249}</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="650">Number of patients retrivied from the hospital files.</participants>
                <participants group_id="P2" count="145"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="405">Number of patients analyzed.</participants>
                <participants group_id="P2" count="145"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="245"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>incomplete data on file</title>
              <participants_list>
                <participants group_id="P1" count="245"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Study Group</title>
          <description>Randomly selected data of 405 patients treated within the last ten years at the study site.</description>
        </group>
        <group group_id="B2">
          <title>Dakahlia Governorate Adult Female Population</title>
          <description>A historical control group derived from the raw data of a previously published study (PMID: 31463388, PMCID: PMC6709406, DOI: 10.1016/j.heliyon.2019.e02249)</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="405"/>
            <count group_id="B2" value="145"/>
            <count group_id="B3" value="550"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age, Customized</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="405"/>
                    <count group_id="B2" value="145"/>
                    <count group_id="B3" value="550"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>&lt; 45 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="127"/>
                    <measurement group_id="B2" value="93"/>
                    <measurement group_id="B3" value="220"/>
                  </measurement_list>
                </category>
                <category>
                  <title>45 years or above</title>
                  <measurement_list>
                    <measurement group_id="B1" value="278"/>
                    <measurement group_id="B2" value="52"/>
                    <measurement group_id="B3" value="330"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="405"/>
                    <count group_id="B2" value="145"/>
                    <count group_id="B3" value="550"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="405"/>
                    <measurement group_id="B2" value="145"/>
                    <measurement group_id="B3" value="550"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race and Ethnicity Not Collected</title>
          <population>Race and Ethnicity were not collected from any participant.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="0"/>
                    <count group_id="B2" value="0"/>
                    <count group_id="B3" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Egypt</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="405"/>
                    <count group_id="B2" value="145"/>
                    <count group_id="B3" value="550"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="405"/>
                    <measurement group_id="B2" value="145"/>
                    <measurement group_id="B3" value="550"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Prevalence of HCV Seropositivity in Breast Cancer Patients.</title>
        <description>Percentage of patients with breast cancer with positive anti-HCV serological test.</description>
        <time_frame>This outcome will be assessed through study completion, an average of 6 months.</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Study Group</title>
            <description>Randomly selected data of 405 patients treated within the last ten years at the study site.</description>
          </group>
          <group group_id="O2">
            <title>Dakahlia Governorate Adult Female Population</title>
            <description>One-hundred forty-five adult females from Dakahlia governorate were sampled in a published population-based cross sectional study from 2015 to 2017.</description>
          </group>
        </group_list>
        <measure>
          <title>Prevalence of HCV Seropositivity in Breast Cancer Patients.</title>
          <description>Percentage of patients with breast cancer with positive anti-HCV serological test.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="405"/>
                <count group_id="O2" value="145"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>anti-HCV Seropositive</title>
                  <measurement_list>
                    <measurement group_id="O1" value="88"/>
                    <measurement group_id="O2" value="15"/>
                  </measurement_list>
                </category>
                <category>
                  <title>anti-HCV seronegative</title>
                  <measurement_list>
                    <measurement group_id="O1" value="317"/>
                    <measurement group_id="O2" value="130"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Fisher exact test was used for testing of association of Breast Cancer diagnosis with anti-HCV test status.</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.0027</p_value>
            <method>Fisher Exact</method>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>2.406</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>1.341</ci_lower_limit>
            <ci_upper_limit>4.316</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Fisher exact test was used to test the association of Breast Cancer diagnosis with anti-HCV test result in women younger than 45 years.</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.0034</p_value>
            <method>Fisher Exact</method>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>7.032</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>1.582</ci_lower_limit>
            <ci_upper_limit>31.25</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Disease-related Events</title>
        <description>The number of events related to breast cancer diagnosis. Disease-free survival (DFS) was calculated as the time from the date of breast cancer diagnosis to the date of last follow-up or the date of first breast cancer-related event. At the time of analysis, median survival has not been reached.</description>
        <time_frame>at the date of last patients' visit recorded on her file. Patients should be censored at least 12 months from the time of diagnosis.</time_frame>
        <population>At the time of analysis, median survival has not been reached. This Outcome Measure was pre-specified to be collected only for the Study Group. The outcome is not applicable to the control group (non-cancer population).</population>
        <group_list>
          <group group_id="O1">
            <title>Anti-HCV Positive Patients</title>
            <description>patients with anti-HCV positive test.</description>
          </group>
          <group group_id="O2">
            <title>Anti-HCV Negative Patients</title>
            <description>patients with anti-HCV negative test.</description>
          </group>
        </group_list>
        <measure>
          <title>Disease-related Events</title>
          <description>The number of events related to breast cancer diagnosis. Disease-free survival (DFS) was calculated as the time from the date of breast cancer diagnosis to the date of last follow-up or the date of first breast cancer-related event. At the time of analysis, median survival has not been reached.</description>
          <population>At the time of analysis, median survival has not been reached. This Outcome Measure was pre-specified to be collected only for the Study Group. The outcome is not applicable to the control group (non-cancer population).</population>
          <units>number of events related to cancer</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="88"/>
                <count group_id="O2" value="317"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="37"/>
                    <measurement group_id="O2" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>All-cause Mortality and Adverse Events were not assessed in this Retrospective, observational study.</time_frame>
      <desc>All-cause Mortality and Adverse Events were not assessed in this retrospective, observational study</desc>
      <group_list>
        <group group_id="E1">
          <title>Study Group</title>
          <description>All-cause Mortality and Adverse Events were not assessed in this retrospective, observational study</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="0"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="0"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>This is a retrospective study. Due to limited funding, a non-selected sample of Breast Cancer was compared to a historical control derived from the data of a previously published population study. Further studies are required.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Osama Hussein</name_or_title>
      <organization>Mansoura University</organization>
      <phone>00201099815110</phone>
      <email>osamahussein@mans.edu.eg</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

